Last reviewed · How we verify
Sustained iron dextran supplementation
Sustained iron dextran supplementation is a Small molecule drug developed by Shanghai East Hospital. It is currently FDA-approved.
Sustained iron dextran supplementation is used to treat conditions such as anemia, critical illness, and chemotherapy-induced anemia. It works by supplementing iron, a necessary component for the production of red blood cells.
At a glance
| Generic name | Sustained iron dextran supplementation |
|---|---|
| Sponsor | Shanghai East Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Practical Anemia Bundle for SusTained Blood Recovery (PHASE2)
- Erythropoietin and Iron Supplementation for Patients With Chemotherapy-induced Anaemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sustained iron dextran supplementation CI brief — competitive landscape report
- Sustained iron dextran supplementation updates RSS · CI watch RSS
- Shanghai East Hospital portfolio CI
Frequently asked questions about Sustained iron dextran supplementation
What is Sustained iron dextran supplementation?
Who makes Sustained iron dextran supplementation?
What development phase is Sustained iron dextran supplementation in?
Related
- Manufacturer: Shanghai East Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing